🔗 Share this article WHO Raises Concern Over Severe Scarcity of Obesity Jabs Less than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy can access them, caution the global health agency as it publishes its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable availability to this class of drugs. Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can help people shift significant weight, says the body. Skinny Jab Scarcity Even in the present most optimistic scenario, the manufacturing of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO. The guideline calls on nations and manufacturers to increase access, via strategies including patent sharing. A patent on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026. How Weight-Loss Drugs Work The injections mimick a natural hormone to delay gastric emptying, curb appetite and increase satiety so individuals reduce food intake. Patients usually see weight reduction in the initial weeks of commencing the regular doses. Studies indicates users may see weight return after a year of halting the treatment, as their normal hunger come back. Being above a healthy weight raises your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity affects individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.
Less than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy can access them, caution the global health agency as it publishes its first guidance on the drugs. Considering in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is urging broader and more equitable availability to this class of drugs. Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "Our new guidelines acknowledges that excess weight is a long-term condition that can be addressed with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and supply-chain constraints are key barriers to broad access to the injections that can help people shift significant weight, says the body. Skinny Jab Scarcity Even in the present most optimistic scenario, the manufacturing of such drugs might only reach about 100 million people – less than 10% of those who need them, as stated by the WHO. The guideline calls on nations and manufacturers to increase access, via strategies including patent sharing. A patent on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026. How Weight-Loss Drugs Work The injections mimick a natural hormone to delay gastric emptying, curb appetite and increase satiety so individuals reduce food intake. Patients usually see weight reduction in the initial weeks of commencing the regular doses. Studies indicates users may see weight return after a year of halting the treatment, as their normal hunger come back. Being above a healthy weight raises your chance for contracting medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies. Obesity affects individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the health agency.